Cyclooxygenase-2 (COX-2) - A Therapeutic Target in Liver Cancer?

Author(s): Marco Breinig, Peter Schirmacher, Michael Andre Kern

Journal Name: Current Pharmaceutical Design

Volume 13 , Issue 32 , 2007

Become EABM
Become Reviewer


Targeting COX-2, a key-enzyme of the prostaglandin metabolism, for the treatment of cancer has been in the focus of researchers for about a decade. However, only recently has this topic been related to hepatocellular carcinoma (HCC). HCC is one of the most common cancers and a growing health problem worldwide. At present, only few promising treatment options are available, accentuating the urgent need for novel therapeutic approaches. Since the first report of COX-2 overexpression in HCC, several findings support the notion that selective COX-2 inhibition proves to be beneficial in this malignancy. This review focuses on recent discoveries regarding the pro-tumorigenic potential of COX-2 in HCC and the functional effects of COX-2 inhibition on molecular mechanisms of this malignancy. Of clinical interest, promising data from in vivo experiments and case studies suggest a beneficial effect of COX-2 inhibitors for HCC- therapy. Detailed analysis of COX-2- activated pathways and related mechanisms may enable the evaluation and design of even more specific and combinatorial treatment approaches in the future.

Keywords: prostaglandins, NSAIDs, Growth Factor Signaling, immune responses, proliferation

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2007
Page: [3305 - 3315]
Pages: 11
DOI: 10.2174/138161207782360627
Price: $65

Article Metrics

PDF: 17